

Experience of MTZ Clinical Research

Early Clinical Development & BE

Lp.	Therapeutic / Chemical subgroup	Chemical substance	Indication / Population
Alimentary tract and metabolism			
1	Drugs used in diabetes	Glimepiride	Healthy subjects
2	Lipid modifying agents	Simvastatin	Healthy subjects
3	Lipid modifying agents	Lovastatin	Healthy subjects
4	Lipid modifying agents	Rosuvastatin	Healthy subjects
5	Lipid modifying agents	Rosuvastatin	Healthy subjects
Antiinfectives for systemic use			
6	Antivirals for systemic use	Aciclovir	Healthy subjects
7	Antivirals for systemic use	Oseltamivir	Healthy subjects
8	Antibacterials for systemic use	Azithromycin	Healthy subjects
9	Antibacterials for systemic use	Azithromycin	Healthy subjects
10	Antibacterials for systemic use	Azithromycin	Healthy subjects
Antineoplastic and immunomodulating agents			
11	Antineoplastic agents	Capecitabine	Healthy subjects
12	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
13	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
14	Taxane	Paclitaxel	Metastatic breast cancer
15	Antineoplastic agents	Capecitabine	Healthy subjects
16	Antineoplastic agents	Capecitabine	Healthy subjects
17	Monoclonal antibodies	Rituximab	Non-Hodgkin Lymphoma
18	Granulocyte colony-stimulating factor	Pegfilgrastim	Neutropenia
19	Antineoplastic agents	Doxorubicin Hydrochloride Liposome	Advanced Carcinoma of the Ovary
Blood and blood forming organs			
20	Antithrombotic agents	Enoxaparin sodium	Healthy subjects
Cardiovascular system			
21	Diuretics	Indapamide	Healthy subjects
22	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
23	Diuretics	Indapamide	Healthy subjects
24	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
25	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
26	Calcium channel blockers	Nitrendypine	Healthy subjects
27	Vasoprotectives	Calcium dobesilate	Healthy subjects
28	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects

Bioequivalence studies

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Early Clinical Development & BE

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Indication / Population
29	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects
30	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects
31	Lipid modifying agents	Simvastatin	Healthy subjects
	Dermatologicals		
32	Monoclonal antibodies	Adalimumab	Healthy subjects
33	Corticosteroids	Mometasone furoate	Healthy subjects
34	Corticosteroids	Mometasone furoate	Healthy subjects
35	Flavonoid	Genistein	Healthy subjects
36	Corticosteroids	Mometasone furoate	Healthy subjects
37	Corticosteroids	Mometasone furoate	Healthy subjects
38	Antipsoriatics	Tacalcitol	Plaque Psoriasis
39	Antipsoriatics	Tacalcitol	Plaque Psoriasis
40	Corticosteroids	Betamethasone dipropionate	Healthy subjects
41		Betamethasone dipropionate and salicylic acid	Healthy subjects
42	Corticosteroids	Betamethasone dipropionate and salicylic acid	Healthy subjects
43	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects
44	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects
	Genito-urinary system and sex hormones		
45	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects
46	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects
	Musculo-skeletal system		
47	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
48	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
49	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
50	Drugs for treatment of bone diseases	Risedronic acid	Healthy subjects
51	Muscle relaxants	Thiocolchicoside	Healthy subjects
52	Antiinflammatory and antirheumatic products	Naproxen	Healthy subjects
53	Drugs for treatment of bone diseases	Alendronic acid	Healthy subjects
	Nervous system		
54	Psychoanaleptics	Amitriptyline	Healthy subjects
55	Psycholeptics	Olanzapine	Healthy subjects
56	Antiepileptics	Topiramate	Healthy subjects
57	Antidepressant	Memantine	Healthy subjects
58	Psychoanaleptics	Amitriptyline	Healthy subjects
59	Antivertigo preparations	Cinnarazinum & Dimenhydrinatum	Healthy subjects

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Early Clinical Development & BE

Lp.	Therapeutic / Chemical subgroup	Chemical substance	Indication / Population
60	Psychoanaleptics	Mirtazapine	Healthy subjects
61	Other nervous system drugs	Betahistine	Healthy subjects
62	Antiepileptics	Topiramate	Healthy subjects
63	Antiepileptics	Pregabalin	Healthy subjects
63	Psychoanaleptics	Aniracetam	Healthy subjects
64	Anti-parkinson drugs	Rasagiline	Healthy subjects
	Respiratory system		
65	Antihistamines	Clemastine	Healthy subjects
66	Nasal preparations	Fluticasone furoate	Healthy subjects
67	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
68	Antihistamines	Loratadine	Healthy subjects
69	Antihistamines	Levocetirizine	Healthy subjects
70	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
	Various		
71	Antiinflammatory / Sympathomimetics	Ibuprofen / Pseudoephedrine	Healthy subjects

Lp.	Therapeutic/Chemical subgroup	Indication / Population
	Alimentary tract and metabolism	
72	Drugs used in diabetes	Impaired Hepatic Function
73	Drugs used in diabetes	Type 2 diabetes mellitus
	Antiinfectives for systemic use	
74	Pharmacokinetic interaction	Healthy subjects
75	Antivirals for systemic use	Healthy subjects
	Antineoplastic and immunomodulating agents	
76	Tyrosine kinase inhibitor (TKI)	Metastatic Solid Tumors
77	Antiparasitic products, insecticides and repellents	Peritoneal cancer
78	Monoclonal antibodies	Rheumatoid arthritis
79	Galectin receptors	Biliary Cancer
80	Bruton's tyrosine kinase inhibitor	Mantle Cell Lymphoma
81	Tyrosine kinase inhibitor (TKI)	Acute Myelogenous Leukemia (AML)
82	Proteasome inhibitor	Multiple Myeloma
83	Protein kinase inhibitors	Healthy subjects
84	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)
85	Interleukin inhibitors	Idiopathic thrombocytopenic purpura
86	Selective Inhibitor of Nuclear Export (SINE)	Diffuse Large B-Cell Lymphoma (DLBCL)
87	Bruton's tyrosine kinase inhibitor	Mantle Cell Lymphoma
88	Monoclonal antibodies	Rheumatoid arthritis
89	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Early Clinical Development & BE

Lp.	Therapeutic/Chemical subgroup	Indication / Population
90	Selective Inhibitor of Nuclear Export (SINE)	Acute Lymphoblastic Leukemia (ALL)
91	Other antineoplastic agents	Multiple Myeloma
92	Antimetabolites	Myelodysplastic syndrome (MDS)
93	Bruton's tyrosine kinase inhibitor	Multiple Myeloma
	Blood and blood forming organs	
94	Recombinant Factor IX	Hemophilia B
	Dermatologicals	
95	Immunosuppressants	Plaque Psoriasis
96	Flavonoid	Plaque Psoriasis
97	Antihistamines	Plaque Psoriasis
98	Antipsoriatics	Healthy subjects
99	Antipsoriatics	Healthy subjects
100	Monoclonal antibodies	Atopic Dermatitis
	Genito-urinary system and sex hormones	
101	Selective progesterone receptor modulator	Uterine fibroids
102	Selective progesterone receptor modulator	Endometriosis
103	Sex hormones and modulators of the genital system	Vasomotor symptoms in Post-Menopausal Women
	Musculo-skeletal system	
104	Protein kinase inhibitors	Healthy subjects
105	Protein kinase inhibitors	Rheumatoid arthritis
	Nervous system	
106	Analgesics	Cancer pain
107	Tyrosine kinase inhibitor (TKI)	Impaired Hepatic Function
108	Tyrosine kinase inhibitor (TKI)	Impaired Hepatic Function
109	Antiepileptics	Neuropathic pain
110	Anesthetics	Impaired Hepatic Function
111	Selective α 1 receptor antagonist	Healthy subjects
112	Anesthetics	Healthy subjects
113	Anti-parkinson drugs	Healthy subjects
	Respiratory system	
114	Prostaglandin D2 receptor	Asthma
115	Monoclonal antibodies	Asthma

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Late Phase Studies in Patients & other Projects

	Lp.	Therapeutic/Chemical subgroup	Indication / Population
		Alimentary tract and metabolism	
	116	Drugs used in diabetes	Type 2 diabetes mellitus
Late Phase Studies		Antineoplastic and immunomodulating agents	
	117	Monoclonal antibodies	Acute Lymphoblastic Leukemia (ALL)
	118	Immunoglobulin	Idiopathic thrombocytopenic purpura
	119	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
	121	Bruton's tyrosine kinase inhibitor	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
	122	Bruton's tyrosine kinase inhibitor	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
	123	Selective immunosuppressants	Acute Lymphoblastic Leukemia (ALL)
	124	TNF- α inhibitors	Rheumatoid arthritis
	125	TNF- α inhibitors	Rheumatoid arthritis
	126	Janus kinase (JAK) inhibitor	Rheumatoid arthritis
	127	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)
	128	Monoclonal antibodies	Multiple Myeloma
	129	Monoclonal antibodies	Rheumatoid arthritis
	130	Proteasome inhibitor	Multiple Myeloma
	131	Monoclonal antibodies	Diffuse Large B-Cell Lymphoma (DLBCL)
	132	Histone deacetylase inhibitor	Diffuse Large B-Cell Lymphoma (DLBCL)
	133	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
	134	Monoclonal antibodies	Multiple Myeloma
	135	Protein kinase inhibitors	Diffuse Large B-Cell Lymphoma (DLBCL)
	136	Monoclonal antibodies	Hodgkin Lymphoma
	137	Protein kinase inhibitors	Myelofibrosis
	138	Monoclonal antibodies	Multiple Myeloma
	139	Tyrosine kinase inhibitor (TKI)	Chronic Myelogenous Leukemia
	140	TNF- α inhibitors	Rheumatoid arthritis
	141	Proteasome inhibitor	Multiple Myeloma
	142	TNF- α inhibitors	Psoriatic arthritis
	143	Proteasome inhibitor	Multiple Myeloma
	144	Immunoglobulin	(AL) Amyloidosis
	145	TNF- α inhibitors	Rheumatoid arthritis
	146	Antimetabolites	Myelodysplastic syndrome (MDS)
	147	FLT3 Inhibitor	Acute Lymphoblastic Leukemia (ALL)
	148	FLT3 Inhibitor	Acute Lymphoblastic Leukemia (ALL)
149	Inhibitor of kinase (PI3K)	Chronic Lymphocytic Leukemia (CLL)	
150	Inhibitor of kinase (PI3K)	Myelodysplastic syndrome (MDS)	
151	Monoclonal antibodies	Gastric cancer	
152	Monoclonal antibodies	Paroxysmal nocturnal hemoglobinuria (PNH)	
		Antiinfectives for systemic use	
	153	Immunoglobulin	Idiopathic thrombocytopenic purpura

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Late Phase Studies in Patients & other Projects

Lp.	Therapeutic/Chemical subgroup	Indication / Population
	Cardiovascular system	
154	Cardiac therapy	Orthostatic Hypotension
155	Vasoprotectives	Telangiectasia and lipodystrophy
	Dermatologicals	
156	Interleukin inhibitors	Plaque Psoriasis
157	Interleukin inhibitors	Plaque Psoriasis
158	TNF- α inhibitors	Plaque Psoriasis
159	Janus kinase (JAK) inhibitor	Plaque Psoriasis
160	Janus kinase (JAK) inhibitor	Plaque Psoriasis
161	Interleukin inhibitors	Plaque Psoriasis
162	TNF- α inhibitors	Plaque Psoriasis
163	Monoclonal antibodies	Plaque Psoriasis
164	Corticosteroids	Acne vulgaris
165	Monoclonal antibodies	Atopic Dermatitis
166	Monoclonal antibodies	Plaque Psoriasis
	Genito-urinary system and sex hormones	
167	Gonadotropin releasing hormone	Endometriosis-associated pain
168	Gonadotropin releasing hormone	Endometriosis-associated pain
	Musculo-skeletal system	
169	Monoclonal antibodies	Osteoarthritis of the hip or knee
170	Monoclonal antibodies	After a Total Knee, Hip, or Shoulder Replacement
171	Janus kinase (JAK) inhibitor	Rheumatoid arthritis
	Nervous system	
172	Inhibitor of Tau protein aggregation	Alzheimer's Disease
173	Inhibitor of Tau protein aggregation	Alzheimer's Disease
	Respiratory system	
174	Drugs for obstructive airway diseases	Chronic obstructive pulmonary disease (COPD)
175	Drugs for obstructive airway diseases	Asthma

Lp.	Type of project	Description	
176	Medical Consulting and Writing	Study design	Antipsoriatics
177	Medical Consulting and Writing	Study design	Inhibitor of Tau protein aggregation
178	Medical Consulting and Writing	Study design	Antihemorrhagics
179	Medical Consulting and Writing	Study design	Antihemorrhagics
180	Medical Consulting and Writing	Study design	Antihemorrhagics
181	Medical Consulting and Writing	Study design	Antihistamines
182	Medical Consulting and Writing	Study design	Antipsoriatics
183	Medical Consulting and Writing	Study design	Cosmetics
184	Medical Consulting and Writing	Oseltamivir	Antivirals for systemic use

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Late Phase Studies in Patients & other Projects

Lp.	Type of project	Description	
185	Medical Consulting and Writing	Thiocolchicoside	Muscle relaxants
186	Medical Consulting and Writing	Study design	Antineoplastic agents
187	Medical Experiment	Cosmetics	Cosmetics
188	Medical Experiment	Dietary supplement	Glycemic Index
189	Medical Experiment	Dietary supplement	Glycemic Index
190	Medical Experiment	Dietary supplement	Functional Cognitive Deficiencies
191	Medical Experiment	Medical device	Healthy subjects
192	Medical Experiment	Medical device	Atrial fibrillation
193	Medical Experiment	Reference range determination	
194	Medical Experiment	Cosmetics	Diffuse Large B-Cell Lymphoma (DLBCL)
195	Medical Experiment	Medical device	Cosmetics
196	Medical Experiment	Medical device	Medical device
197	Medical Experiment	Cosmetics	Medical device
198	Medical Experiment	Medical device	Cosmetics
199	Medical Experiment	Medical device	Medical device
200	Medical Experiment	Cosmetics	Aphthous Ulcers
201	Medical Experiment	Cosmetics	Cosmetics
202	Medical Experiment	Dietary supplement	Water retention problems
203	Medical Experiment	Oral gel suspension	Aphthous Ulcers
204	Medical Experiment	Herbal preparation	Alopecia areata
205	Survey to evaluate the readability and usefulness of package leaflet	Leaflet	Reference range determination
206	Survey to evaluate the readability and usefulness of package leaflet	Leaflet	Calcium channel blockers
207	Survey to evaluate the readability and usefulness of package leaflet	Leaflet	ACE inhibitor

Study in Smokers:

Lp.	Type of project	Description	
208	Evaluation the exposure to selected smoke constituents in smokers	Smokers	Medical Experiment
209	Comparing the levels of biomarkers of exposure in smokers	Smokers	Medical Experiment
210	Evaluating the changes in biomarkers of cardiovascular risk in adult smokers	Smokers	Medical Experiment

Date of issue: May 2017

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN

